GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

The pharmaceutical firm said the jab ‘elicited an immune response’ in those at increased risk of RSV due to underlying medical conditions. The immune response was not inferior to those seen in adults aged 60 and above, so the trial met its primary endpoint.

Arexy is already approved in the US to prevent respiratory syncytial virus lower respiratory tract disease in adults 60 years of age and older. It is also approved in Europe and Japan.

‘This trial reinforces our confidence in our RSV vaccine’s ability to help protect adults aged 50 to 59 at increased risk for RSV-LRTD. We will submit these data for regulatory review as quickly as possible with the goal of offering adults in this age group the option of a vaccine for the first time,’ Chief Scientific Officer Tony Wood said.

GSK said it is on track to be the first firm to submit RSV jab data for the 50 and above population. Regulatory decisions are expected next year.

Shares in the company rose 0.7% to 1,480.03 pence each in London on Wednesday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.